Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc reported its interim results for the first half of 2025, showing a revenue of £24.2 million, in line with expectations for the full year. Despite a decrease in revenue and EBITDA compared to the previous year, the company is optimistic about returning to growth in 2026. The integration of recent acquisitions, CRS and Cryostore, is nearing completion, with sales synergies being realized. The company has signed significant contracts, including a £3.2 million hLAB contract and a letter of intent for a major Phase III human challenge trial. hVIVO’s diversification strategy is showing early success, with a strong sales pipeline and new service lines contributing to future growth prospects. The company expects to achieve high-single digit revenue growth in 2026 as market conditions normalize.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £11.50 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.
The overall stock score reflects strong valuation and financial performance, with a low P/E ratio and robust revenue growth. However, technical analysis indicates bearish trends, which slightly offset the positive valuation and financial metrics. The absence of earnings call data means corporate events were not factored into the score, although they present a positive outlook.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase Contract Research Organisation (CRO) and a global leader in human challenge trials. The company offers end-to-end clinical development services to a diverse client base, including major biopharma companies. Specializing in human challenge trials for infectious and respiratory diseases, hVIVO operates the largest quarantine facility in London and provides comprehensive laboratory services under the hLAB brand. Through its subsidiaries, CRS and Venn Life Sciences, hVIVO offers early-phase clinical trial services and consulting to the biopharma sector.
Average Trading Volume: 1,772,640
Technical Sentiment Signal: Sell
Current Market Cap: £67.88M
See more data about HVO stock on TipRanks’ Stock Analysis page.